Market Cap (In EUR)
112.53 Million
Revenue (In EUR)
2.22 Million
Net Income (In EUR)
-19.71 Million
Avg. Volume
1276.00
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 6.4-9.9
- PE
- -
- EPS
- -
- Beta Value
- 0.193
- ISIN
- FR0012634822
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Herve Affagard
- Employee Count
- -
- Website
- https://www.maatpharma.com
- Ipo Date
- 2021-11-08
- Details
- MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
More Stocks
-
HIKALHikal Limited
HIKAL
-
0591C HIGHPRECISION
0591
-
EVSBY
-
TLLTFTILT Holdings Inc.
TLLTF
-
605336
-
004360Sebang Co., Ltd
004360
-
HOLM-BHolmen AB (publ)
HOLM-B
-
4333Taleem REIT Fund
4333